Rising India Inc (OTCMKTS: RSII) Continues Its Aggressive Foray Into The Cannabis Industry

To many people, the mere mention of the phrase “cannabis legalization” conjures up thoughts of out of control parties by young people that smoke cannabis on a daily basis and have a complete lack of direction or motivation, and can now do so with no legal consequence. While there is some of this taking place, whether cannabis is legal or not, there is emerging a more serious and practical side to the legalization of cannabis.Lately, it seems that new discoveries for serious, and practical medicinal uses of cannabis are being made on a regular basis. The convergence of the “Baby-Boomer” population entering into the senior citizen phase of their life, and the cannabis legalization wave that is sweeping the country presents an opportunity for which Rising India Inc (OTCMKTS:RSII) is aggressively moving to capitalize on.The U.S. population dynamics of the next few decades will see the largest portion of the population (the baby-boomers) entering into a phase of life that typically requires a great deal of medical care. This will spur an increase in the demand for health care in general, including the demand to alternative treatment, medications, and therapies. Cannabis is already being used for cancer treatment and pain management. Other uses for medical cannabis include treatment of conditions such as seizure disorders, multiple sclerosis, Parkinson's disease, rheumatoid arthritis, glaucoma and Crohn's disease. Many of these ailments are common among the senior citizen population.Rising India Inc is entering the cannabis at the right time. The merger with Rising BioSciences, Inc. places RSII right into the fold of serious research and development of new alternative treatment, medications, and therapies.On Mar 06, 2017 Rising India Inc. announced that it was preparing to execute the final documents for the incoming merger of Rising BioSciences, Inc., a research and development company focusing on oral and topical pharmaceuticals with strict standards set forward by the pharmaceutical compounding industry. As a result of the merger, Rising India CEO, Jim DiPrima agreed to resign as an officer with the Company making way for the appointment of Robert Weber, who also serves as CEO for PAO Group, listed on the OTC Markets as New Wave Holdings Inc (OTCMKTS:NWAV). CEO Jim DiPrima feels this will be an incredible opportunity for the company and its shareholders moving forward. Incoming management and strategic alliances include a team of chemists, physicians, pharmacists and Medical Marijuana Industry veterans for the development of products in a clinical lab environment.

"I feel that Rising BioSciences will deliver shareholder value in a big way," states DiPrima. "There are ample prospects within the MMJ R&D markets, particularly those budding in the pharmaceutical compounding sector. Rising BioSciences seeks to fulfill a yet-to-be-met market demand with a first to market approach so that patients across the U.S. get the treatment they so desperately need without falling subject to the dangers of opiates, whose long-term effects can include liver damage, dependence/addiction and brain damage due to hypoxia, resulting from respiratory depression, among other complications."

RSII stock has been on a upward trend since the beginning of 2017. It made a strong upward spike with strong volume on February 28, 2017 topping out at $.0290 before retracing to $.0060. It is now trading at $.0120. Fourth quarter financials for 2016 are yet to be reported. Revenues over the last year are showing an increase. Current market capitalization stands at $4.65 million, on 387.14 million shares outstanding as of March 31, 2017The appointment of Robert Weber as CEO of Rising India, who also serves as CEO for PAO Group, listed on the OTC Markets as New Wave Holdings, presents and interesting dimension to the Rising India Inc. merger. New Wave Holdings has recently launched several alternative medicine clinics (with more openings planned) focused on 'non-traditional' patient care solutions, including cannabis related medicines, treatments, and therapies. PAO Group is actively developing alternative medicine clinics focused on the proper use of cannabis for treatment of chronic and terminal patients. Robert Weber, being CEO of both companies, is strategically positioned with Rising BioSciences researching and producing alternatives pharmaceuticals, and PAO Group clinics delivering them to patients. This type of vertical integration should result in growth for both companies. We will be updating our subscribers as soon as we know more. For the latest updates on RSII, sign up below!Disclosure: We have no position in any of the securities mentioned and have not been compensated for this article.